This is a working overview of Pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，含非天然氨基酸残基 |
| 分子量 | 711.85 g/mol | 理论值，盐形式可能略有差异 |
| 外观 | 白色至类白色粉末 | 冻干粉常见 |
| 溶解性 | 易溶于水 | 也可溶于部分极性有机溶剂 |
| 储存条件 | -20°C，干燥避光 | 长期保存通常推荐 |
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
=== Paraguay === The president of the Authentic Radical Liberal Party, Hugo Fleitas, applauded Maduro's capture, stating that "We celebrate the liberation of Venezuela from the oppressive regime of dictator Maduro" and "we hope for the restoration of democracy based on respect for the self-determination of the Venezuelan people, expressed at the polls in 2024 with the election of Edmundo González as their president." The Guasú Front issued a statement condemning the strikes, labelling as an "intolerable military aggression against Venezuela and all of Latin America."
== Signs and symptoms == The first skin changes in calciphylaxis lesions are mottling of the skin and induration in a livedo reticularis pattern. As tissue thrombosis and infarction occurs, a black, leathery eschar in an ulcer with adherent black slough develops. Surrounding the ulcers is usually a plate-like area of indurated skin. These lesions are always extremely painful and most often occur on the lower extremities, abdomen, buttocks, and penis. Lesions are also commonly multiple and bilateral. Because the tissue has infarcted, wound healing seldom occurs, and ulcers are more likely to become secondarily infected. Many cases of calciphylaxis lead to systemic bacterial infection and death. Calciphylaxis is characterized by the following histologic findings:
The four substrates of this enzyme are 4-hydroxybenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are protocatechuic acid, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxybenzoate,NAD(P)H:oxygen oxidoreductase (3-hydroxylating). Other names in common use include 4-hydroxybenzoate 3-monooxygenase (reduced nicotinamide adenine, dinucleotide (phosphate)), 4-hydroxybenzoate-3-hydroxylase, and 4-hydroxybenzoate 3-hydroxylase. This enzyme participates in benzoate degradation via hydroxylation and also uses flavin adenine dinucleotide as a cofactor.
The period of Italian colonial rule saw the widespread adoption of pasta and lasagne, especially in the south. Tea and coffee are also really popular. Somalis were among the early adopters of coffee consumption, and Somali merchants were some of the first traders to export coffee beans. Somali coffee, known locally as 'Qahwo' and tea 'Shah', stand out due to their preparation method, which involves selecting various spices to enhance their flavour profile. 'Xalwo', which is closely associated with Omani 'Halwa', is a smooth jelly-like treat that is made with spices, seeds, nuts, and caramelised sugar. This confection is commonly served together with Somali 'Qahwo'. After meals, homes are traditionally perfumed using frankincense or incense (unsi), which is prepared inside an incense burner referred to as a dabqaad.
Sources: en.wikipedia.org
=== Tonus Therapeutics === After completing his formal education, Sachs taught organic chemistry at Chaminade College School followed by a position as a staff fellow at the National Institutes of Health. In 1978, he accepted an assistant professor position in the University at Buffalo's Department of Pharmacology. In this role, Sachs discovered mechanosensitive ion channels which are sensors for systems including the senses of hearing, touch, and balance. As a result of his discovery, he also created the only drug to inhibit these channels. Sachs believed that spider venom could contain molecular compounds that could block the ion channels. After discovering the possibility of a drug, he was contacted by several large pharmaceutical companies but none offered to adopt the drug. He eventually co-launched Rose Pharmaceuticals in 2009, which was named after Sachs’ pet tarantula and grandmother, with a stockbroker named Harvey whose grandson had had Duchenne muscular dystrophy. The following year, the Food and Drug Administration designated the firm’s peptide, called GsMTx4, as an orphan drug for Duchenne muscular dystrophy. In 2012, Sachs and Harvey opened their first-ever headquarters in UB’s New York State Center of Excellence in Bioinformatics and Life Sciences and re-named the company Tonus Therapeutics. Within two years, the company sold the rights to their drug to Akashi Therapeutics. He also began studying AT-300’s effectiveness in dystrophic mice.
== Use on farms == From 2000 to 2005, the US Department of Agriculture National Agricultural Statistics Service survey of dairy producers found that about 17% of producers used rBST. The 2010 USDA National Agricultural Statistics Service survey of Wisconsin farms found that about 18% of dairy farms used rBST and 56% of dairy cows were given rBST.
=== Meteoritic quinones === A proposed alternative source to chemiosmotic energy developing across membranous structures is if an electron acceptor, ferricyanide, is within a vesicle and the electron donor is outside, quinones transported by carbonaceous meteorites pick up electrons and protons from the donor. They would release electrons across the lipid membrane by diffusion to ferricyanide within the vesicles and release protons which produces gradients above pH 2, the process is conducive to the development of proton gradients.
==== Breast-filler toxicity ==== Biological risks to the health of a sucking infant arise from the possibility of breast-filler toxicity, that the filler-material (saline solution or silicone gel) might leak from the breast-implant into the body of the mother, then into her breast milk, and then into the infant organism; yet the biological risk to the breastfeeding infant is minimal, because silicone is indigestible and saline-solution is digestible. The study Silicone Breast Implants and Breastfeeding (1996) indicated that possible medical complications that impede breastfeeding can arise among women with silicone-filled prosthetic breasts, and found no causal relation between the presence of breast prostheses and neurological and physical impairment of the breastfeeding function of the augmented breasts.
Since 2000, neonatal screening of sickle cell disease has been performed at the national level for all newborns defined as being "at-risk" for sickle cell disease based on ethnic origin (defined as those born to parents originating from sub-Saharan Africa, North Africa, the Mediterranean area (South Italy, Greece, and Turkey), the Arabic peninsula, the French overseas islands, and the Indian subcontinent). Since 3 August 2024, this screening is systematically applied to all newborns in France.
Sources: en.wikipedia.org
Jean-Louis Sebagh is an Algerian-born French cosmetic surgeon and doctor who is known for his anti-aging surgeries, and use of botox, collagen and vitamin injections specifically on the face and neck. Sebagh's high profile clients including numerous celebrities, models and socialites include Cindy Crawford, Elle McPherson and Kylie Minogue. and he has offices in Paris and London.
SlimPort, a brand of Analogix products, complies with Mobility DisplayPort, also known as MyDP, which is an industry standard for a mobile audio/video Interface, providing connectivity from mobile devices to external displays and HDTVs. SlimPort implements the transmission of video up to 4K-UltraHD and up to eight channels of audio over the micro-USB connector to an external converter accessory or display device. SlimPort products support seamless connectivity to DisplayPort, HDMI and VGA displays. The MyDP standard was released in June 2012, and the first product to use SlimPort was Google's Nexus 4 smartphone. Some LG smartphones in LG G series also adopted SlimPort. SlimPort is an alternative to Mobile High-Definition Link (MHL).
=== Disadvantages === Reduced immunogenicity compared to attenuated vaccines Require adjuvants to improve immunogenicity Often require multiple doses ("booster" doses) to provide long-term immunity Can be difficult to isolate the specific antigen(s) which will invoke the necessary immune response It is not easy to supervise conjugation chemistry which leads to noncontinuous variation
Several state courts and officials, including the Colorado Supreme Court, a state Circuit Court in Illinois, and the Secretary of State of Maine, ruled that Trump was ineligible to hold office under Section 3 of the Fourteenth Amendment to the United States Constitution for his role in the January 6 Capitol attack, and thus attempted to disqualify him from appearing on the ballot. These attempts were unsuccessful. On March 4, 2024, the U.S. Supreme Court unanimously ruled in Trump v. Anderson that states cannot determine eligibility for a national election under Section 3. The Court held that only Congress has the authority to disqualify candidates, or to pass legislation that allows courts to do so.
=== EC 1.14.11 With 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors === EC 1.14.11.1: γ-butyrobetaine dioxygenase EC 1.14.11.2: procollagen-proline dioxygenase EC 1.14.11.3: pyrimidine-deoxynucleoside 2′-dioxygenase EC 1.14.11.4: procollagen-lysine 5-dioxygenase EC 1.14.11.5: Now included with EC 1.14.11.6 thymine dioxygenase EC 1.14.11.6: thymine dioxygenase EC 1.14.11.7: procollagen-proline 3-dioxygenase EC 1.14.11.8: trimethyllysine dioxygenase EC 1.14.11.9: flavanone 3-dioxygenase EC 1.14.11.10: pyrimidine-deoxynucleoside 1′-dioxygenase EC 1.14.11.11: hyoscyamine (6S)-dioxygenase EC 1.14.11.12: gibberellin-44 dioxygenase EC 1.14.11.13: gibberellin 2β-dioxygenase EC 1.14.11.14: Now EC 1.14.20.13, 6β-hydroxyhyoscyamine epoxidase EC 1.14.11.15: gibberellin 3β-dioxygenase EC 1.14.11.16: peptide-aspartate β-dioxygenase EC 1.14.11.17: taurine dioxygenase EC 1.14.11.18: phytanoyl-CoA dioxygenase EC 1.14.11.19: Now EC 1.14.20.4, anthocyanidin synthase EC 1.14.11.20: deacetoxyvindoline 4-hydroxylase EC 1.14.11.21: clavaminate synthase EC 1.14.11.22: Now EC 1.14.20.5, flavone synthase EC 1.14.11.23: Now EC 1.14.20.6, flavonol synthase EC 1.14.11.24: 2′-deoxymugineic-acid 2′-dioxygenase EC 1.14.11.25: mugineic-acid 3-dioxygenase EC 1.14.11.26: deacetoxycephalosporin-C hydroxylase EC 1.14.11.27: [histone H3]-dimethyl-L-lysine36 demethylase EC 1.14.11.28: proline 3-hydroxylase EC 1.14.11.29: hypoxia-inducible factor-proline dioxygenase EC 1.14.11.30: hypoxia-inducible factor-asparagine dioxygenase EC 1.14.11.31: thebaine 6-O-demethylase EC 1.14.11.32: codeine 3-O-demethylase EC 1.14.11.33: DNA oxidative demethylase EC 1.14.11.34: Now EC 1.14.20.7, 2-oxoglutarate/L-arginine monooxygenase/decarboxylase (succinate-forming) EC 1.14.11.35: 1-deoxypentalenic acid 11β-hydroxylase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.37: kanamycin B dioxygenase EC 1.14.11.38: verruculogen synthase EC 1.14.11.39: L-asparagine hydroxylase EC 1.14.11.40: enduracididine β-hydroxylase EC 1.14.11.41: L-arginine hydroxylase EC 1.14.11.42: tRNAPhe (7-(3-amino-3-carboxypropyl)wyosine37-C2)-hydroxylase EC 1.14.11.43: (S)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.44: (R)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.45: L-isoleucine 4-hydroxylase EC 1.14.11.46: 2-aminoethylphosphonate dioxygenase EC 1.14.11.47: [50S ribosomal protein L16]-arginine 3-hydroxylase EC 1.14.11.48: xanthine dioxygenase EC 1.14.11.49: uridine-5′-phosphate dioxygenase EC|1.14.11.50: Now EC 1.14.20.8, (–)-deoxypodophyllotoxin synthase EC 1.14.11.51: DNA N6-methyladenine demethylase EC 1.14.11.52: validamycin A dioxygenase EC 1.14.11.53: mRNA N6-methyladenine demethylase EC 1.14.11.54: mRNA N1-methyladenine demethylase EC 1.14.11.55: ectoine hydroxylase EC 1.14.11.56: L-proline cis-4-hydroxylase EC 1.14.11.57: L-proline trans-4-hydroxylase EC 1.14.11.58: ornithine lipid ester-linked acyl 2-hydroxylase EC 1.14.11.59: 2,4-dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase EC 1.14.11.60: scopoletin 8-hydroxylase EC 1.14.11.61: feruloyl-CoA 6-hydroxylase EC 1.14.11.62: trans-4-coumaroyl-CoA 2-hydroxylase EC 1.14.11.63: peptidyl-lysine (3S)-dioxygenase EC 1.14.11.64: glutarate dioxygenase EC 1.14.11.65: [histone H3]-dimethyl-L-lysine9 demethylase EC 1.14.11.66: [histone H3]-trimethylL-lysine9 demethylase EC 1.14.11.67: [histone H3]-trimethyl-LL-lysine4 demethylase EC 1.14.11.68: [histone H3]-trimethyl-L-lysine27 demethylase EC 1.14.11.69: [histone H3]-trimethyl-L-lysine37 demethylase EC 1.14.11.70: 7-deoxycylindrospermopsin hydroxylase EC 1.14.11.71: methylphosphonate hydroxylase EC 1.14.11.72: [2-(trimethylamino)ethyl]phosphonate dioxygenase EC 1.14.11.73: [protein]-arginine 3-hydroxylase EC 1.14.11.74: L-isoleucine 31-dioxygenase EC 1.14.11.75: 31-hydroxy-L-isoleucine 4-dioxygenase EC 1.14.11.76: L-glutamate 3(R)-hydroxylase EC 1.14.11.77: alkyl sulfatase
Sources: en.wikipedia.org
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。
生长激素释放激素通过其专用受体起作用，而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放，但信号通路和下游效应并不相同。
研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限，长期结局尚不明确。
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.